# EARly Prevention of aTHeroma Progression

Study · id `cardio:ct-nct02105623` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02105623](<https://clinicaltrials.gov/study/NCT02105623>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02105623

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 111 participants.

## Technical summary

Registry record NCT02105623. Randomized; no masking; primary purpose treatment. Start 2014-06 (actual); primary completion 2018-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 111 participants (enrolled count; ClinicalTrials.gov record NCT02105623, source copy `cardio:ctgov-nct02105623-2018-06-25`, retrieved 2026-10-26)
- Started: 2014-06 (actual) (ClinicalTrials.gov record NCT02105623, source copy `cardio:ctgov-nct02105623-2018-06-25`, retrieved 2026-10-26)
- Primary completion: 2018-03 (actual) (ClinicalTrials.gov record NCT02105623, source copy `cardio:ctgov-nct02105623-2018-06-25`, retrieved 2026-10-26)
- Completion: 2018-03 (actual) (ClinicalTrials.gov record NCT02105623, source copy `cardio:ctgov-nct02105623-2018-06-25`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02105623, source copy `cardio:ctgov-nct02105623-2018-06-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02105623-2018-06-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: EARly Prevention of aTHeroma Progression
- Acronym: EARTH
- Condition: Coronary Arteriosclerosis
- Intervention (Behavioral): Standard Therapy
- Intervention (Drug): Rosuvastatin
- Lead sponsor: CHEOL WHAN LEE, M.D., Ph.D
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: CHEOL WHAN LEE, M.D., Ph.D (`cardio:org-cheol-whan-lee-m-d-ph-d`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)

## Provenance

Content hash: 0219cff666eacfa452d812d4645766ce030c3e53f55e1cdc7898e1b7592bea7e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
